Overview

Everything registered for Autonomix in 00-admin/artifacts.json, generated from the approved PreWiki projection

One line

Autonomix Medical, Inc. (Nasdaq: AMIX) is a medical device company "developing Biosignal

Category

Biosignal Intelligence: stated as "a new category" the company is developing (manuscript

Business model

Pre-revenue, investigational. The deck's planned model: single-use diagnostic sensing

Products and pipeline

Sensing Catheter · Biosignal Intelligence Procedural Guidance Platform · RF Ablation Catheter:

Evidence position (Sep 2026)

cancer pain, single site in Uzbekistan; PoC 1 n=20 enrolled / 19 treated; PoC 2 enrolling. The

• Human: one first-in-human PoC study of transvascular RF ablation for severe pancreatic
• Preclinical: porcine renal sensing studies (2024, 2026); GLP study completed 2026-08-12.
• Regulatory: nothing cleared or approved; IDE / De Novo (releases) and 510(k) (deck) plans

Current priorities (as the sources state them)

1. Reposition the company from "sensing + ablation for cancer pain" to Biosignal

Overview

What this is. The as-built design system of the 2026 Autonomix website, extracted

1. The brand in one paragraph

Autonomix Medical, Inc. (NASDAQ: AMIX) is developing Biosignal Intelligence: "a new

2. The system in one paragraph

A black stage lit from inside. #000000 and navy #070B12 carry the page; Autonomix Orange

3. Colour

Full palette, contrast table, pixel share and the build defect:

4. Typography

Two self-hosted families, mirrored to Brand Assets/Fonts/ (latin + latin-ext only; the

• Archivo, variable 400, 700. Display and headings. Declared stack
• Chakra Petch, static 400 / 500 / 600. Body, UI, eyebrows, buttons, nav. Stack
• Both carry metric-matched fallbacks (size-adjust, ascent/descent overrides on local

Scale, as measured at 1920

Four details carry the type voice and are easy to lose in a rebuild:

Overview

Short list. Break one and the asset is off-brand: or, for the claims lines, a regulatory and

Colour

1. The ground is black #000000 or navy #070B12. Light grounds exist only to explain

Type

7. Archivo for display (700; 400 for statements), Chakra Petch for everything else: as

Logo

11. Use only Brand Assets/Logos/Primary/ (client lockup) and Site-2026/. The corporate

Surfaces and motion

14. Every bordered surface gets the gradline: 1px orange → cyan, top to bottom. No flat grey

Language

19. Capabilities are always hedged: is developing, is designed to, is working to, has

Core lines

Boilerplate (web, manuscript About): "Autonomix Medical, Inc. is a medical device company

The story, in order

1. The Missing Signal. Procedures are guided by anatomy, averages and indirect measures;

Vocabulary

Use (client wording): Biosignal Intelligence · low-amplitude biosignals / signals · at the

Sample lines (built only from sourced copy)

source and turn them into real-time procedural guidance and treatment confirmation.

• Headline: Illuminating the Nervous System.
• Problem: Anatomy shows where to treat. It can't always show what the physiology is doing.
• Platform: Biosignal Intelligence is designed to capture low-amplitude neural signals at their
• Physician hook: What if nerves could answer back?
• Milestone post: Our GLP preclinical study is complete, a key step toward our planned FDA

Editing checklist

0. No "mapping"? 1. Every capability hedged? 2. The three verbs in order? 3. "Low-amplitude", not "ultra-low", on

Overview

Autonomix has no customer yet. It has constituencies, and every asset is written for exactly

1. Investors: primary today

conference audiences (H.C. Wainwright, Maxim, LSI, Octane, Benzinga, Webull, Virtual Investor).

• Who: retail and institutional holders of AMIX; microcap healthcare investors; analysts;
• Where they meet the brand: press releases, CEO Corner, Virtual Investor segments, the
• What they need to believe (deck): a differentiated sensing-and-AI platform, a large market
• Pains / objections (inferred): repeated dilution (two reverse splits, frequent raises);
• Language they get: "Invest in What's Next." "Window to Enter is Open Now." Comps, TAM,

2. Interventional physicians and KOLs: primary for the platform

hypertension/RDN specialists, interventional radiologists and oncologists (cancer pain),

• Who: interventional cardiologists and electrophysiologists (EP mapping, AF/VT ablation),
• Where: CRT, TCT, EuroPCR, CIRSE, SIR, SIO, ECIO, ASCO GI, SSO, DDW; peer abstracts; the
• Job to be done (manuscript): "understand what is happening physiologically, guide
• Pain, in the client's words: procedures "guided by anatomical landmarks, population
• Objections (inferred): preclinical-only sensing data; signal-to-noise credibility at
• Hook they respond to: "What If Nerves Could Answer Back?" (deck slide 4; manuscript T1).

3. Strategic partners and acquirers

Medtronic, J&J MedTech, Philips) and RDN system makers.

• Who: EP, cardiology and denervation strategics (the deck's comps: Boston Scientific,
• What they need: an add-on sensing/confirmation layer "with Potential Compatibility Across
• Rule: never imply a partnership, acquisition interest or exit.

4. Clinical research partners and sites

Basel, Beth Israel/Harvard, Fels Medical (see leadership-governance).

• Current human study site is in Uzbekistan; U.S. sites are future. Scientific advisors at UBC,

5. Media and prospective employees (secondary)

• Media reach the company through JTC Team IR/PR. Careers content does not exist.

There is nothing to sell yet

Autonomix is pre-revenue and investigational. The deck targets commercial launch at the end of

Pipeline (manuscript)

"Designed to Work Independently or as an Intelligent Closed Loop."

Investor proposition (deck, Aug 2026)

Five investment pillars (slide 12): Deep IP ("112 issued and pending patents") · Proprietary

Sales-enablement assets that exist

reviewer-note slides that must be stripped before external use (Q-12).

• Investor deck, Aug 2026 (client drive), the only current deck. Includes appendix and
• Website manuscript, 8-27-26 (client drive) and the PreHealth-built site and wireframe.
• CEO Corner and Virtual Investor video segments (IR record).
• No one-pager, fact sheet, KOL deck or conference kit exists in the drive.

Overview

The evidence Autonomix can stand on, with the words that must travel with each number. Full

People

Investor-deck proof points: see Source Register once the deck extraction

Channels (source-backed, legacy site 2026-09-01)

The new site build links bare facebook.com / x.com / linkedin.com: placeholders; use the

What Autonomix actually publishes (inferred from 139 releases)

Social is IR-led: almost every post amplifies a press release. There is no evidence of

Rules for any Autonomix post

1. One milestone, one line, one link (to ir.autonomix.com or the release PDF).

Not defined

Posting cadence, owner (JTC vs Autonomix vs PreHealth), approval workflow, hashtags, paid social,

Where Autonomix says it enters

Initial commercial indication: resistant hypertension, via renal denervation (RDN). "We are

• CONFIRM DENERVATION, "Shows neural response where no confirmation workflow exists."
• MAP BETTER, "Adds local neural context to electrophysiology mapping."

Market size: as the deck states it

Releases use only "multi-billion-dollar" and, once, "a $100 billion market opportunity"

Named competitors: renal denervation (deck slide 36)

The deck positions Autonomix alongside ablation systems (it is a sensing/confirmation layer),

Adjacent landscape: mapping and EP (inferred from the deck)

(a Boston Scientific / Rhythmia catheter: general knowledge, not stated in the deck): i.e. Autonomix is positioning the sensing catheter in the EP

• The Gen 1 510(k) predicate is the INTELLAMAP ORION™ High Resolution Mapping Catheter
• Oncology-pain comparators in the releases: "opioids or invasive ethanol injections" (the

Strategic comparables (deck slides 17, 37)

These are investor-context comps. Never place them in physician-facing or public web copy,

Named in meetings

perform 'mapping'."

• 9/17: Medtronic and Abbott professionals told the team the platform "does not technically
• 8/31: benchmark "Neuro One" (probably NeuroOne Medical, unverified). 9/24: Precision

Overview

Companion to Master Brand Guide. This page is the how it is assembled

Composition grammar: the homepage, top to bottom

The homepage is six sections plus footer. Each has its own ground; the ground change is the

1. Light-in-the-dark imagery (signature)

Every hero-level image is rendered anatomy or hardware glowing orange on black: the translucent

2. The gradline

Every bordered surface: masthead pill, signal cards, flow cards: carries a 1px (2px on flow

3. The copy wipe

Copy never fades or slides. It wipes through a 105° soft-edged gradient mask

4. The progress rail and the signal line

A 1px track with orange fill and three glowing ticks marks progress through each pinned film.

Overview

How any Oracle agent (PreSocial, PreDeck, PreQA, copy, design) works on Autonomix.

Read in this order

1. Claims & Compliance: the fence. Nothing ships that breaks it.

Always

investor asset.

• Put an investigational statement on every external asset; forward-looking statements on every
• Hedge every capability: is developing, is designed to, has the potential to.
• Attribute all human data to RF ablation with commercially available catheters, never to
• Write every number with study, n, timepoint and analysis type; date every patent count.
• Use Brand Assets/Logos/Primary/autonomix-logo-primary.svg (light ground) or the
• Score the output with the rubric (gate 80) and list any hard fail.

Never

"breakthrough", "GPS for the nervous system", or "AI-powered" standing alone.

• Say "mapping" about the platform (9/17 decision), "cleared", "approved", "first", "only",
• Use deck-only names (Lattice™ AI, Neural Signal Index™, Metis, Precision Pilot, Signature IQ,
• Publish a regulatory date, a market size, or the 18/12 family count.
• Generate a likeness of a real person (founders, advisors, patients) without documented consent.
• Present the as-built Archivo type system to the client as approved (Q-21).

When sources conflict

Stop, name both sources, and add the conflict to open-questions. Trust order: original

Escalate to a human

Any clinical, regulatory, securities or patient-facing claim; anything headed to the client; any

Overview

Autonomix is an investigational medical device company and a Nasdaq issuer. Every external

Mandatory lines

Investigational status: one of these on every external asset. Three versions exist; until

Blocked until sourced or operator-approved

Per the PreHealth onboarding method, these are blocked unless the figure is in

• any clinical percentage, VAS change, responder rate, opioid or quality-of-life figure;
• any market size (the releases' "$100 billion market opportunity" (2024-04-16) is unsourced);
• any regulatory designation, pathway or timeline;
• any "first", "only", "first-in-class", "first-ever", "breakthrough", "revolutionize";
• the prototype sensing figures (< 5 µV, 0.02 × 0.03 mm, 16/40) without their "prototype"
• acquisition values in leadership bios (WATCHMAN "$1B revenues" / "multi-billion-dollar"
• Landy Toth's patent count (250+ vs 730+, Q-15);
• deck-only names (Lattice™ AI, Neural Signal Index™, Metis, Precision Pilot, Catalytic Neuro)

Standing qualifiers: the metric sentence

Every clinical number is written with study · population · n · timepoint · analysis in the

Superlatives the company itself uses

The IR boilerplate says "first-in-class platform system technology", "revolutionize", "for the

Legacy public copy: do not carry forward

The current public autonomix.com (snapshot 2026-09-01) says "the world's first GPS for the

Overview

Score any Autonomix asset before it leaves the building. Gate: 80/100, with hard fails that

Scoring

Score = Σ points out of 100. ≥80 ships, 70: 79 returns with named fixes, <70 is a rebuild.

Not yet derived

known-good and known-bad assets. Run that validation before it gates production.

• No approved Autonomix creative corpus exists, so this rubric has not been validated against
• Deck, social and email rubrics are not written separately; the investor deck in the client
• Claims checks will tighten once the client supplies its own compliance rules (Q-06).

Read this first

1. All human data so far is RF ablation with commercially available catheters, not sensing.

Human: first-in-human proof-of-concept: pancreatic cancer pain

Design (2024-02-06, 2025-09-03). Transvascular RF energy to ablate nerves associated with

Lead-in, n=5 (2024-06-18, 2024-09-09)

(from baseline of 8.0 to 1.67)."

• 7 days: "60% of subjects responded with a mean 6.33 reduction of pain on the VAS pain scale
• 4, 6 weeks: "60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain
• No immediate procedure-related complications or significant adverse events (n=5).

Interim, first 15 (2024-10-31)

post-procedure"; "clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain

• "79% responder rate achieved with zero opioid use and quality of life improvement at 7 days

PoC 1 final, n=20 enrolled (2025-04-30)

(6 deaths from disease before 4: 6-week follow-up; 2 hospitalizations). 14 AEs, including 8

• 19 of 20 treated; one not treated (celiac trunk stenosis prevented catheter placement).
• No device- or procedure-related serious adverse events. 8 SAEs, all reported as unrelated
• Access: 16 femoral, 100% responded; 3 brachial, no improvement ("a key procedural learning").
• mITT (n=19): 7 days, mean VAS −3.32 (7.61 → 4.29), 43.6%; 4, 6 weeks, −3.95 (7.95 → 4.00),
• Femoral responders (n=16, 84% of treated): 7 days, −4.16 (7.81 → 3.65), 53.3%; 4, 6 weeks,
• Femoral responders, quality of health / functional / symptomatic QoL: 7 days +76% / +33% / +37%;
• Opioids: 100% of responders at zero opioid use at 7 days; 73% at 4, 6 weeks.
• 3 patients' 4, 6-week VAS missing (unable to travel due to disease progression).

PoC 1 longer-term post hoc (2025-09-03)

• Responders (n=6): mean VAS −5.08 (7.75 → 2.67), 65.6%.
• Responders (n=7): 100% opioid-free at 3-month follow-up.
• Responders (n=6): global health +76.5%, functional +51.5%, symptom +50.4% (means).
• Significance as stated: relief at 24 hours p<0.001; sustained to 3, 5 months p<0.005.

Overview

The public record, compiled. One row per milestone that changes what we can say about the

How the story changed

them "in one simple procedure"; "first-in-class catheter-based sensing technology"; lead

• 2023, 2025: "two-fold technology" that detects problematic neural signals and ablates
• 2026: Biosignal Intelligence, a sensing-and-intelligence platform (Acquire · Interpret ·

Clinical and technical terms (general)

Related: technology-platform · clinical-program

The approved-looking line (manuscript, Aug 2026)

> "Autonomix is protected by exclusive rights to a rapidly growing global intellectual property

The count has moved: and the site contradicts itself

The new site would state a lower count (112) than the live site (120+). Confirm before launch.

Founder patents

"Landy Toth … named on 250+ patents spanning neural sensing, microelectronics and signal

Rights history

$8M: "Autonomix now wholly owns development and commercialization rights to its technology in

• Dec 2021: cardiology-field licence to Impulse Medical, Inc.
• Jul 2023: licence termination agreement.
• 2024-01-30: exclusive worldwide cardiology-field rights regained for a warrant valued at
• 2024-07-15: non-exclusive, perpetual, royalty-free licence to RF Innovations' Apex 6

Grants announced (headlines, abbreviated)

Titles and numbers for every grant: read the release (links in

Overview

Company: Autonomix Medical, Inc. · Nasdaq: AMIX (listed 2024-01-29) · Delaware

Co-founders

Founding idea (site): "greater visibility into the nervous system could enable more informed,

Management team

Also named in releases: Julie Manchester, VP Regulatory Affairs and Quality (2024-12-19);

Scientific advisors (manuscript)

Other KOLs in the IR record: Dr. Toufic Kachaamy, City of Hope (SSO 2026 data; "What This

Investor relations

autonomix@jtcir.com.

• IR / media contact (press releases): JTC Team, LLC, Jenene Thomas, 908.824.0775,
• Site footer (build): investors@autonomix.com, (888) 555-1234, the phone number is a
• IR channels: CEO Corner video segments (launched 2024-07-11), Virtual Investor "What This
• Manuscript routing rules: CEO Corner moves into Investor Relations; the full news archive

Capital history (gross, as announced)

IPO $11.2M (Jan 2024) · public offering ~$10.0M (Nov 2024) · warrant exercises $2.5M (Jul 2025) ·

What it is, in the company's words

> "Biosignal Intelligence is Autonomix's integrated architecture for acquiring complex

Designed around the signal: prototype figures

From the Technology page (T2). The wireframe's claim-care note: these are prototype figures:

Signal deconstruction and AI guidance

biosignals, separating overlapping electrical activity and isolating individual signal

• Deconstruction (T3): algorithms "designed to deconstruct complex, ultra-low-amplitude
• AI guidance (T4): "proprietary custom-built AI system is designed to identify patterns and

Product pipeline (manuscript T6)

> "Designed to Work Independently or as an Intelligent Closed Loop: Each product is being

Hardware facts from the IR record

"through and beyond the lumen wall" (2026-05-19 patent release).

• Transvascular. Everything is catheter-based, from inside the vasculature, targeting nerves
• ASIC. Custom application-specific integrated circuit; next generation developed with
• "Microchip-based sensing antenna array", the 2025-08-14 description of the sensing
• Apex 6 generator. RF Innovations' FDA-cleared generator for lesioning neural tissue for
• Basket catheter render. The site's section-3 plate shows a multi-electrode basket

Investor-deck detail (Aug 2026, SRC-020): internal / investor use

The deck goes further than the manuscript. Everything here is investor-deck language and

Overview

Nothing in this brain is approved. Every note is draft. The brand design system, voice,

• 2026-09-08, Jennifer Cook (CBO) tracked-change revision of the website manuscript, including

Brain (required notes)

All present, all draft. None approved.

• [x] 00-admin/source-register.md
• [x] 02-foundation/client-overview.md
• [x] 03-brand/master-brand-guide.md
• [x] 03-brand/voice-messaging.md
• [x] 04-audience/audience-icp.md
• [x] 05-offers-sales/offers-sales-context.md
• [x] 06-content-social/content-social-system.md
• [x] 07-market-competitors/market-competitors.md

Before any Autonomix asset ships

• [ ] PreHealth owner approves the brand sections (approval-log.md)
• [ ] Q-21 typeface decided (Aptos vs Archivo)
• [ ] Q-08 investigational wording chosen
• [ ] Q-06 client compliance rules received

Before the new website launches (target mid-October, possibly November)

• [ ] Q-02 patent families corrected (18 vs 12) and count dated
• [ ] Q-15 founder patent count confirmed (250+ vs 730+)
• [ ] Q-05 JVIR citation confirmed
• [ ] Q-23 safety headline and hematoma footnote reconciled (Clinical Evidence verbatim block)
• [ ] Q-01 .section--light fixed; Q-07 IR contact and social URLs replaced
• [ ] Q-27 homepage news-card dates matched to real releases
• [ ] Q-16 / Q-24 founder imagery with documented consent; og.jpg, apple-touch-icon
• [ ] Q-25 production stack confirmed (WordPress + Salient) and design system ported

Before PreWiki emission

(the draft run is PreHealth-inc/PreWiki#4, merged for the Oracle portal with

• [ ] Approval recorded; Q-21 resolved; logo rules (Q-04) defined
• [ ] Run scaffold-design-system.mjs --client Autonomix against an approved brand-spec

Oracle portal (prehealth-oracle-portal, #/client/autonomix)

The portal is a snapshot baked from the vault by bake.js; the 2026-09-15 bake predates this

• [ ] Merge PreHealth-inc/PreWiki#4 (Design System, brand-spec, portal-safe styleguide fonts)
• [ ] Merge PreHealth-inc/oracle#2 (this brain, brand guide, 03-brand/design-tokens.json,
• [ ] bake.js: ship oracle/08-clients/active//knowledge-system/site/ (non-.md) into
• [ ] Portal data/knowledge-systems.json: add autonomix from
• [ ] Portal data/client-blurbs.json: "autonomix": "Illuminating the Nervous System, a
• [ ] Run node bake.js, deploy, and check #/client/autonomix:
• Knowledge system card reads 156 docs · 2,455 facts · 20 connections · 763 claim risks and
• Design system card opens the interactive brand guide (Archivo + Chakra Petch load, logo

Positioning and naming

low and high-amplitude physiological signals." Targets: renal denervation and cardiology (AFib,

• 8/31: position as "bio signal intelligence" rather than "nerve sensing", "to capture both
• 8/31 tagline candidates: "making invisible physiology visible," "illuminating the nervous
• 9/3: "Established the core messaging framework around the concept of 'Illuminating the
• 9/14: "Terminology shifted to position technology as a mapping tool" after cardiology
• 9/17, reversal: after talking with Medtronic and Abbott professionals, "the platform does

Visual system

branding are preserved without modification." Dark mode confirmed; limit animation and

• 8/31: "Corporate logo and branding retained", "the existing Autonomix corporate logo and
• 9/3: the animated human-body storytelling concept chosen over a bento-grid concept.
• 9/9 (internal): "Standardized the project typography to the Adobe Aptos font"; "avoiding
• 9/14: "Aptos approved as display and body font"; Chakra Petch "specifically for numbers
• 9/17: cut copy by up to 50%; the rendered electrodes "resembled bubbles", client to supply
• 9/24 (internal): homepage restructure (Precision Neuroscience as reference): Dr. Schwartz

Build and IR

build on Vercel is a prototype. IR runs separately (Barry; a third-party SEC-data plugin); the

• 9/14: production framework WordPress + Salient theme (Doug Cress), the PreHealth static
• 8/31: Clinical Evidence copy to stay verbatim from existing materials "to avoid the need
• 8/31: investor deck to avoid "over-branding"; John Ryan flagged that high-fidelity 3D AI

Timeline

mid-October" (Brad Hauser managing).

• 9/9: 4-page website scope. 9/17: launch "may push… to November instead of

Transcription errors (do not propagate)

"Jennifer Rossley" = Jennifer Cook (CBO; invited as jcook@autonomix.com) · "Autonomics" =